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Abstract
Objective—To evaluate whether hormonal contraceptives, used before or in early pregnancy, 
confer increased risk of preterm birth or reduced fetal growth.
Design—Population-based cohort study conducted by the Norwegian Institute of Public Health 
(Mother and Child Cohort Study, 1998-2008) with linkage to the Norwegian Prescription Registry 
and to the Medical Birth Registry of Norway.
Setting—Norway
Population—Of the 48,615 pregnancies meeting study inclusion criteria, 44,734 pregnancies 
were included in the complete case analysis.
Methods—We characterized hormonal contraception by type (combination oral, progestin only 
oral, vaginal ring, transdermal, and injectable) and specific progestin component. We used 
generalized estimating equations to estimate the odds of adverse outcome according to 
formulation used. Several sensitivity analyses were conducted.
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Main outcome measures—Preterm birth, small for gestational age
Results—We observed a positive association between use of a combination oral contraceptive 
and preterm birth for all exposure periods (e.g., adjusted OR: 1.21, 95% CI: 1.04, 1.41 for last use 
12 to >4 months before conception); combination contraceptives containing the progestin 
norethisterone were consistently related to risk. Other types of hormonal contraception were 
generally not associated with preterm birth; none were related to small for gestational age. 
Observed associations were robust to sensitivity analyses.
Conclusion—Hormonally active agents may exert dose-, agent-, and timing-specific effects on 
growth and development. We found that the particular progestin component is important when 
assessing the potential for adverse effects among former users of hormonal contraceptives.
Keywords
Mother and child Cohort Study (MoBa); preterm birth; small for gestational age; hormonal 
contraceptives
Introduction
Exposure to hormonally active agents during pregnancy has been inversely associated with 
duration of gestation and fetal growth1-3. Much of the literature concerning exposure to 
hormonally active agents has been centered on exposure to environmental compounds that 
may have endocrine effects. However pharmacologic agents may also contribute. For 
example, in women undergoing fresh embryo-based transfer for in vitro fertilization, 
increased levels of endogenous estrogen at the time of blastocyst implantation, as a result of 
ovarian hyperstimulation from gonadotropins, may contribute to an increased risk of preterm 
birth 4, 5. In sows, administering 17β-estradiol throughout pregnancy suppressed offspring 
growth in early life; in mice 6, administering diethylstilbestrol in early neonatal life resulted 
in an initial decrease in offspring growth 7.
Possible adverse effects, resulting from use of hormonal contraceptives in pregnancy have 
been studied, with mixed evidence as to whether use is associated with preterm birth or 
altered fetal growth. These former studies generally had limited statistical power and most 
used older statistical methods for data analyses 8-11. Some of the variability in results from 
these studies may also be attributable to differences in the contraceptives assessed. The 
effects of hormonal contraceptives vary and are largely driven by the progestin component 
and the pharmacodynamics of progestin and ethinyl estradiol taken in combination. For 
example, some progestin formulations, such as levonorgestrel, are androgenic, while others, 
such as drospirenone, have no affinity for androgen receptor binding.12, 13 The capacity of 
the progestin to bind to androgen, mineralocorticoid, and glucocorticoid receptors is thought 
to be a major determinant of the differential actions of progestins in eliciting adverse 
metabolic effects in women.12, 14-18 These effects are similar to the metabolic changes that 
occur in women who are overweight or obese.19,20 In the animal models, maternal obesity 
has led to an increase in the number of apoptotic follicles in the ovaries, smaller and fewer 
oocytes, and smaller pups at birth.21, 22 To our knowledge, there are no studies of the 
association between hormonal contraceptive use and birth outcomes whereby exposure to 
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hormonal contraceptives was evaluated according to progestin type. We are also not aware 
of any studies evaluating birth outcomes for users of the progestin-only oral contraceptive. 
Given the differences in metabolic effects from hormonal contraceptive formulations with 
varying progestin components, and the relationship between maternal metabolic factors and 
offspring birth outcomes, evaluating the association between hormonal contraceptive by 
progestin type is warranted. These associations may not be limited to exposures incurred 
during pregnancy. In animal models, developmentally sensitive periods begin even before 
conception. Specifically, the recruitment of a follicle for selection as a dominant follicle and 
oocyte maturation can be influenced by exposure to hormonally active agents.23-27.
In the present study we used the Norwegian Mother and Child Cohort Study (MoBa), a 
population-based cohort study conducted by the Norwegian Institute of Public Health,28, 29 
to evaluate the association between hormonal contraceptive use before and in early 
pregnancy, and birth outcomes. The MoBa data were linked to the Medical Birth Registry of 
Norway (MBRN) and to the Norwegian Prescription Registry (NorPD). In linking to the 
prescription registry, the formulation of hormonal contraceptive could be evaluated with 
finer detail than has been described previously.
Methods
Primary analyses
Study population—MoBa study participants were recruited from 1999 through 2008. 
Women were identified for eligibility when scheduling the routine prenatal ultrasound 
offered free of charge to all pregnant women in Norway at 17-20 weeks of gestation. 
Women were then mailed an invitation to participate before the scheduled ultrasound, with 
informed consent and enrollment taking place at the ultrasound examination. All hospitals 
with at least 100 births per year participated in the study recruitment and enrollment. 
Approximately 42 percent of all pregnant women in Norway were invited to participate in 
the study. Of these, 39 percent consented to participate. At enrollment, participants were 
asked to provide a blood sample and to complete an initial, self-administered questionnaire 
to provide data on demographic characteristics, reproductive health history, disease and 
medication history, lifestyle factors, and socioeconomic status. Follow-up is ongoing and is 
conducted through self-administered questionnaires at regular intervals and by linkage to 
national health registries.
All MBRN birth registry data are collected on a standardized birth notification form 
completed by the midwife or physician attending the birth. Prescription data from NorPD 
contains individual-level data on all medications prescribed and dispensed through 
pharmacies to non-institutionalized individuals in Norway. By Norwegian law, as of January 
1, 2004, all pharmacies must provide electronic data for all prescriptions dispensed.
There were 107,308 pregnancies in the MoBa cohort (cohort Version 6). For the present 
analysis, we included pregnancies resulting in a singleton live birth and excluded 
pregnancies with documentation of infertility treatment for the index pregnancy, on either 
the MoBa 17-week questionnaire or the MBRN. We additionally excluded pregnancies to 
women who had documented pre-pregnancy chronic hypertension (n=527). As the NorPD 
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registry was not initiated until January 1, 2004, we further restricted our study population to 
pregnancies of women enrolled at least 12 months after the date on which the NorPD 
registry began collection of data on prescription fills (n=48,615). We excluded pregnancies 
with missing covariate data (n=4,191). The final study population included 44,734 
pregnancies to 42,155 women (Figure 1).
All Norwegian residents are assigned a personal identifier number. Linkage of the MoBa 
questionnaire, MBRN, and NorPD data files were possible through this identifier. The 
University of North Carolina at Chapel Hill and the National Institute of Environmental 
Health Sciences Institutional Review Boards and the Norwegian Southeastern Regional 
Ethics Committee reviewed and approved this study.
Exposure
Dispensing of hormonal contraceptives prior to conception and in early pregnancy was 
ascertained via linkage to the Norwegian Prescription Registry Database. These 
contraceptives were characterized according to the Anatomical Therapeutic Chemical (ATC) 
Classification System. We characterized exposure by type and route of administration 
(combination oral contraceptive, progestin-only oral contraceptive, vaginal ring, 
transdermal, injectable, implant, and hormonal-based intrauterine device), the approach most 
similar to previous studies evaluating the relationship between hormonal contraceptive use 
and adverse pregnancy outcomes. Because of the heterogeneity in hormonal contraceptive 
progestins in their specificity for binding to the progesterone receptor, we also characterized 
exposure by type, route, and progestin component. All hormonal contraceptives with an 
estrogen component (combination oral contraceptives, vaginal ring, and the transdermal 
contraceptive) contained ethinyl estradiol, but there were eight different progestin types used 
solely or in combination with ethinyl estradiol, including desogestrel, drospirenone, 
levonorgestrel, norelgestromin, norethisterone, lynestronol, medroxyprogesterone, and 
etonogestrel. Date of conception was estimated by subtracting 17 days 30 from the total 
number of days of gestation (to account for the follicular phase prior to conception) and then 
subtracting this value from the date of birth. We used the last menstrual period (LMP)-based 
estimated gestational length unless the LMP-based gestational length was missing or ≥2 
weeks different from the ultrasound-based estimate of gestational length, in which case we 
used the ultrasound-based measure 31. We then constructed an exposure window for each 
hormonal contraceptive prescription filled using the date that the prescription was filled and 
the number of defined daily doses dispensed (day’s supply). We characterized exposure into 
discrete categories relative to conception: last use 12 - >4 months before, 4 - >1 months 
before, and 1 - >0 months before, and 0 -12 weeks after. Women using hormonal 
contraceptives in early pregnancy were also using hormonal contraceptives before 
pregnancy. In our analyses, we evaluated outcomes among those within a category of date of 
last use as compared to those with no hormonal contraceptive use within any of the other 
exposure periods assessed.
Most oral contraceptives were dispensed in 3-month supply (82%) or 6-month supply 
(15%). For pregnancies with more than one type of hormonal contraceptive prescribed, we 
assigned exposure type according to the type of contraceptive used closest to the estimated 
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date of conception. Because many women may choose to stop taking their hormonal 
contraceptive in order to achieve conception, we characterized women as exposed in early 
pregnancy only if they reported on the 17-week questionnaire that the pregnancy was 
unplanned and they had ≥1 day(s) supply of hormonal contraceptive at or after the day of 
conception as defined above.
Outcome
Preterm birth was defined as delivery before 37 completed weeks of pregnancy 32. Small for 
gestational age (SGA) was characterized as having been born at <3rd percentile for weight 
for gestational age 33, 34. Birthweight z-score was calculated by subtracting the observed 
birthweight from the expected birthweight based on the population standard distribution (at 
that gestational age) and then dividing this value by the standard deviation for each 
gestational age.
Covariates
We used a Directed Acyclic Graph (DAG) approach35 to identify a minimally sufficient set 
of adjustment factors. The selected covariates included in the DAG were factors 
demonstrated to be antecedents of both hormonal contraceptive use and preterm birth or 
weight for gestational age, including maternal age (14-19, 20-29, 30-39, 40-49) 36, 37, 
maternal pre-pregnancy BMI (kg/m2)(<18.5, 18.5-24.9, ≥25.0) 37, 38, parity (0, 1, ≥2) 39, 
maternal smoking (none, quit, smoker) 37, 40, and maternal education (>4 years of university 
or technical, 4 year university or technical degree, 3 years of college preparatory high 
school, 3 years of technical high school, 1-2 years of high school, <9 years of secondary 
school, other) 41,42. In the analyses we restricted the study population to women without 
chronic hypertension and adjusted on BMI, age, parity, smoking, and education.
Analysis
Our primary analyses were concerned with assessing the association between hormonal 
contraceptive use, by type (combination versus progestin-only) and route (oral, vaginal, 
transdermal, and injectable), and preterm birth or SGA within the discrete categories of 
period of last use as listed above. For each exposure period, any contraceptive with <10 
exposed cases were combined into a single “other” exposure category. We used generalized 
linear models with a logit link, and generalized estimation equations (GEE) with an 
independent correlation matrix 43 to estimate associations between exposures and outcomes 
using robust standard errors, accounting for lack of independence between siblings.
We conducted likelihood ratio tests to assess whether the model fit for preterm birth or SGA 
was improved by characterizing exposure with increasing detail. We used generalized linear 
models to obtain the log likelihood for three, nested models; first modeling any hormonal 
contraceptive use in each of the exposure periods as compared to no use at any of the 
exposure periods, second, hormonal contraceptive use by type and route as compared to no 
use, and third, contraceptive use by type, route and progestin formulation as compared to no 
use. All analyses were conducted using SAS v9.3 (SAS Inc., Cary, North Carolina).
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Examination of the covariate distribution among pregnancies with hormonal contraceptive 
use in early pregnancy, as compared to non-users, indicated that women with hormonal 
contraceptive use were generally older and more parous than non-users (Table S1). There 
were also differences in the characteristics of women using different types of hormonal 
contraceptives. For example, while 71% of combination oral contraceptive users were 
nulliparous, just 17.2% of progestin-only oral contraceptive users were nulliparous. These 
differences suggest that prescribing patterns may differ based on individual factors, thus 
raising concern about confounding by indication. We explored the robustness of our results 
through sensitivity analyses designed to mitigate the potential for confounding by indication.
First, because combination oral contraceptive users were much likely to be nulliparous than 
progestin-only oral contraceptive users, we restricted our analysis to nulliparous pregnancies 
only. Next, we compared the association comparing combination oral contraceptive use to 
vaginal ring use (Table S1), because these two groups were socio-demographically similar. 
Also, to assess whether factors associated with having an unplanned pregnancy (e.g. prenatal 
care or other behavioral factors) could be confounding the results observed, we restricted 
our analysis of exposure at 0 -12 weeks after conception to women reporting an unplanned 
pregnancy, specifically, users of a hormonal contraceptive as compared to unplanned 
pregnancies not using a hormonal contraceptive. Finally, we conducted a propensity score 
analysis to reduce residual confounding associated with use of combination oral 
contraceptives as compared to no use of a hormonal contraceptive.
To construct the propensity scores, we evaluated several models to estimate the predicted 
probability of obtaining a combination oral contraceptive prescription (propensity for 
treatment scores). We included in the models those factors believed to be associated with 
both use of the combination oral contraceptive and preterm birth (parity, maternal pre-
pregnancy body mass index, maternal age, maternal education, maternal smoking), but that 
preceded the use of a combination oral contraceptive. We compared the distribution of 
propensity scores among those prescribed a combination hormonal contraceptive to those 
not prescribed any hormonal contraceptive, to evaluate evidence of common support, and 
trimmed any observations where there was no corresponding propensity score. We then 
ranked the scores into deciles and assigned each observation a corresponding rank. We used 
GEE models to assess the relationship of combination oral contraceptive use with preterm 
birth, with inclusion of an indicator term for rank, and obtained a pooled estimate of the 
association across strata. In addition to the term for rank, these models included all of the 
potential confounders from the primary analyses models 44-46. The distribution of study 
covariates for the exposed and unexposed was similar within propensity score rank (Table 
S2).
Results
As noted above, 44,734 pregnancies met the inclusionary criteria. Of these, nearly all were 
to women between the ages of 20-39 (97%), approximately half were first pregnancies 
(47.1%), and the majority had at least some college education (81.4%). Roughly a third of 
the pregnancies (30.7%) were in women who were overweight or obese (Table 1).
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There were 1,969 (4.4%) births before 37 completed weeks of gestation and 1,167 (2.6%) 
infants were SGA. Relative to conception, 7,470 pregnancies were last exposed 12 to >4 
months before, 5,740 were exposed 4 to >1 months before, 6,465 were exposed 1 to >0 
months before, and 1,638 were exposed 0 to 12 weeks after.
In evaluating hormonal contraceptive use by type and route of administration, we observed a 
positive association between use of a combination oral contraceptive and preterm birth, with 
the magnitude of the association remaining relatively consistent regardless of the exposure 
period (Table 2). For the progestin-only oral contraceptive, we observed an inverse 
association with preterm birth for use 1 to >0 months before conception (aOR: 0.67, 95% 
CI: 0.46, 0.97) and a positive, but statistically non-significant association for each of the 
other exposure periods. Other associations with preterm birth were not observed, except use 
of an injectable contraceptive at 12 - >4 months before conception was positively associated 
with preterm birth (aOR: 1.83, 95% CI: 1.06, 3.18). Data were too sparse to evaluate the 
association between the injectable and preterm birth for any of the other exposure periods. 
The direction of the association between use of a hormonal contraceptive and gestational 
length, in days, was generally consistent with the estimates obtained from modeling the 
association with preterm birth.
When characterizing exposure by type, route, and progestin component, likelihood ratio 
tests indicated improved model fit (p<0.05) for exposure 4 to >1 months before, 1 to >0 
months before, and 0 to 12 weeks after conception. For example, for exposure 0 - 12 weeks 
after conception, the magnitude of the association for use of a combination oral 
contraceptive with norethisterone was much stronger (aOR: 3.33, 95% CI: 1.69, 6.57) than 
the magnitude of the association for the combination oral contraceptive containing 
drospirenone (aOR: 1.17, 95% CI: 0.76, 1.80). Similarly, by evaluating the progestin-only 
oral contraceptive by progestin type, we observed a strong association between use of the 
norethisterone progestin-only oral contraceptive 0 - 12 weeks after conception and preterm 
birth (aOR: 2.02, 95% CI: 1.03, 1.79). Data were too sparse to evaluate other forms of the 
progestin-only oral contraceptive by progestin type for exposure 0 - 12 weeks after 
conception.
Norethisterone in the combination oral contraceptive was significantly, positively associated 
with preterm birth across all exposure periods, with the exception of use 1 - >0 months 
before, which was statistically non-significant. A trend in association magnitude across the 
four periods was not supported (p=0.41). Norethisterone in the progestin-only oral 
contraceptive was not associated with preterm birth at any of the other exposure periods 
(Table 3); however a test of homogeneity of aOR across the four exposure periods suggested 
no difference (3 d.f., p=0.14).
Levonorgestrel was the most commonly prescribed progestin type in combination oral 
contraceptives in this data. With the exception of use at 4 - >1 month before (aOR: 1.40, 
95% CI: 1.15, 1.70), there was little evidence to support an association between 
levonorgestrel in the combination oral contraceptive and preterm birth (Table 3).
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Data were too sparse for evaluating use of desogestrel in early pregnancy, however 
desogestrel was significantly, positively associated with preterm birth for use 1- >0 months 
and 12 - >4 months before conception. Use of desogestrel 4 ->1 month before suggested a 
positive, but non-statistically significant association with preterm birth (Table 3).
With the exception of use 12 - >4 months before conception, the combination oral 
contraceptive containing drospirenone progestin was generally not associated with preterm 
birth. Etonogestrel, in the vaginal ring, and norelgestromin, in the transdermal hormonal 
contraceptive, were also not associated with preterm birth in any of the exposure periods 
(Table 3).
Medroxyprogesterone was the only progestin used as an injectable among women in this 
sample and, as described above, was moderately associated with preterm birth for exposure 
12 - >4 months before conception (Table 3).
For formulations where sufficient data were available for analyses, we observed no 
association between use of hormonal contraceptives and increased odds of SGA or 
decreased birthweight z-score (Tables S3-S4). We observed an inverse relation with use of a 
progestin-only oral contraceptive and SGA for exposure 4 – >1 month before and 1 – >0 
months before conception. Sparse data precluded evaluation of the association between early 
pregnancy use of a progestin-only oral contraceptive and SGA (Table S3), as well as 
individual progestin types for the progestin-only oral contraceptive (Table S4).
In sensitivity analyses, estimates observed in our primary analyses were robust to restriction 
of the study sample to nulliparous pregnancies (Table S5). When restricting the comparator 
population to vaginal ring users within the same exposure period, the magnitude of the 
association observed for combination oral contraceptive users and preterm birth 
strengthened (aOR 12 - >4 months: 1.78, 95% CI: 0.99, 3.21), however the wider confidence 
intervals reflect the markedly reduced sample size for these analyses (Table S6). The results 
of the sensitivity analysis evaluating early pregnancy hormonal contraceptive users as 
compared to unplanned pregnancies without hormonal contraceptive use attenuated the 
estimates observed in the primary analysis (aOR 1.22, 95% CI: 0.91, 1.63 vs aOR 1.32, 95% 
CI 1.01, 1.73). The estimate for the combination oral contraceptive containing 
norethisterone remained significantly, positively associated with preterm birth (aOR: 3.00, 
95% CI: 1.53, 5.83) (Table S6). The association between the combination oral contraceptive 
and preterm birth, at all exposure periods, was similarly robust to approaches employing 
propensity scores (Table S7).
Discussion
Main findings
In the present study, use of some formulations of hormonal contraceptives, especially oral 
contraceptives, was associated with preterm birth. The associations observed varied by 
timing and progestin component, with norethisterone and desogestrel showing the strongest 
magnitude of association.
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For preterm birth, the positive association for the combination oral contraceptive was 
observed across all exposure periods. The consistency in the magnitude of the association 
across exposure periods could be evidence of an association with long-term (>12 months) 
use, in which case proximity of last exposure to conception may be less important.
For inadvertent use of hormonal contraceptives early in pregnancy a few suggestive findings 
were seen; however, there was no convincing evidence of a causal relationship with preterm 
birth, and no positive association with SGA was observed.
Strengths and limitations
We used multiple approaches to explore the sensitivity of the estimates to various 
assumptions made in the analysis, including restriction to nulliparous pregnancies, 
unplanned pregnancies, and use of a propensity score to ensure covariate balance in the 
exposed and unexposed groups. As with all observational studies, there remains the potential 
that residual confounding is contributing to the estimates observed.
The association between the combination oral contraceptive and preterm birth was generally 
robust to several sensitivity analyses evaluating potential for uncontrolled confounding in 
our primary analyses. The sensitivity analysis examining use of a hormonal contraceptive in 
early pregnancy as compared to other women experiencing an unplanned pregnancy resulted 
in an attenuation of estimates, with the exception of the norethisterone-containing 
formulation, which remained significantly associated with preterm birth. However, there 
may be factors we did not include in our models -- factors not in our dataset that lead to 
differential use of hormonal contraceptives and that were associated with pregnancy 
outcomes. For example, the specific hormonal contraceptive prescribed is influenced by an 
individual woman’s estrogen, progesterone, androgen sensitivities 12 and these could 
confound the association between hormonal contraceptives and preterm birth. Still, the 
propensity score models provide additional support for the associations observed in our 
primary analyses, assuming we accurately predicted prescribing of a combination oral 
contraceptive.
Although use of a pharmacy-based registry offers the benefit of studying specific 
formulations of contraceptives dispensed at specific times, the registry data are only a proxy 
for actual use of the contraceptives. Data quality measures are in place for assuring the 
NorPD is accurate and complete 47. A validation study of hormonal contraceptive use in the 
NorPD was conducted in adolescents and indicated a sensitivity of 99% and a specificity of 
76% for the NorPD as compared to self-reported use 48. In adolescents, hormonal 
contraceptives may be provided at no cost to the individual, but in adults, hormonal 
contraceptives are not a reimbursable prescription. This may increase the likelihood that a 
dispensed prescription will be used by the individual. Classification of exposure in early 
pregnancy was limited to pregnancies reported to be unplanned to increase the potential that 
prescribed contraceptives were actually being used, but for exposure in other periods before 
pregnancy, fewer women may have been taking a hormonal contraceptive than estimated. 
The consistent attenuation in adjusted associations at the 1 - >0 months before conception 
exposure interval, as compared to other exposure periods, may reflect the higher potential 
for misclassification in this exposure period. In some instances, data were too sparse to 
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evaluate all formulations at every exposure period, limiting our capacity to explore 
differences.
Interpretation
As noted above, previous studies of hormonal contraceptive use in pregnancy and 
gestational length at birth or size at birth had limited statistical power and were 
underpowered for evaluating formulation-specific effects10, 11, 49-52. Nonetheless, their 
results suggest a possible, albeit small, negative association between in utero exposure to 
hormonal contraceptives and birth weight (Table 4). Contemporary approaches to evaluating 
birthweight or low birthweight have shifted toward assessment of birthweight z-scores or 
small for gestational age as these metrics take into account gestational age 53. Applying 
these contemporary approaches to assessing weight at birth, we found little evidence to 
support an association with birthweight z-score or small for gestational age. The association 
with birthweight observed in these previous studies may reflect birth after a shorter 
gestation. For two of these studies, investigators did not evaluate gestational length at birth. 
In two other studies, investigators evaluated gestational length; with one small study 
suggestive of a weak, positive association.
Several studies have assessed the association between use of hormonal contraceptive before 
pregnancy and outcomes at birth, including birthweight 10, 11, 49-52 and gestational 
length 50, 51. In general, these studies suggest a small, negative association between use of 
an oral contraceptive before pregnancy and birthweight. For preterm birth, findings have 
been mixed 50, 51. The apparent lack of consistency in results between studies may be 
attributable to several factors, including differences in formulations, timing of exposure, 
differences in outcome characterization, such as in using birthweight as opposed to 
birthweight z-score or weight for gestational age, small sample limitations, differential 
confounding patterns, or chance.
In the present study, we found that use of a combination oral contraceptive before 
pregnancy, for all exposure periods examined, was associated with preterm birth. The 
combination oral contraceptive was not associated with weight for gestational age, while use 
of a progestin only oral contraceptive was negatively associated with small for gestational 
age at birth. Compared to former studies10, 11, 49-52, the present project had the benefit of a 
larger sample size, improved capacity to evaluate formulation-specific effects, better 
investigation of the potential for confounding by indication, and use of contemporary 
metrics for weight at birth.
Unusually high concentrations of endogenous estradiol due to ovarian hyperstimulation is 
associated with impaired fetal growth 54, 55. In the present study, however, exogenous 
estrogen at the time of conception was unrelated to fetal growth. The estrogenicity of the 
hormonal contraceptives studied may have been too low to affect growth. The weakly 
estrogenic environmental contaminant bisphenol A was recently associated with impaired 
fetal growth 56; that association, however, could be independent of estrogenicity. The 
hormonally active agent DDE, a degradation product of the insecticide DDT, has been 
shown to be antiprogestogenic 57 and has been associated with preterm birth 58. The 
association of norethisterone-containing contraceptives with preterm birth seen here 
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suggests that agents disrupting normal progesterone signaling may increase risk of preterm 
birth, but other possibilities exist. The variation in effects of hormonal contraceptives is 
largely driven by the progestin component. The capacity of the progestin to bind to 
androgen, mineralocorticoid, and glucocorticoid receptors is thought to be a major 
determinant of the differential actions of progestins in eliciting adverse effects 14.
Conclusion
Pharmacologic sources of exposure to hormonally active agents are prevalent due to the 
frequent use of hormonal contraceptives among women of childbearing age. The results of 
this study suggest that certain formulations of hormonal contraceptives may increase risk for 
preterm birth. We found that the particular progestin component is important when assessing 
the potential for adverse effects among former users of hormonal contraceptives. Additional 
resources are needed to evaluate the reproducibility of these findings as these findings 
potentially have important clinical implications for women and their future pregnancies. 
Should the results of this study be replicated in additional studies, clinicians prescribing 
hormonal contraceptives may need to be selective in the formulations they prescribe for 
women planning to conceive at a later date.
Although this is the largest study to date, examining the association between hormonal 
contraceptive use and preterm birth or small for gestational age, the relatively small number 
of exposed cases for some formulations limited study power. The sample size was restricted 
by the fact that the Norwegian Prescription registry did not begin until 2004, over 5 years 
after the MoBa cohort enrollment began. The Danish National Birth Cohort (DNBC) would 
offer the opportunity to study these associations with a larger sample, as the prescription 
registry predates the initiation of the DNBC.
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Table 3
Hormonal contraceptive use and preterm birth by period of last use relative to conception, progestin type, and 
route of administration
Exposure Exposed(n) Preterm (n) OR (95% CI) aOR
a
 (95% CI)
None 23,421 964 referent referent
0 - 12 weeks after
Combination OC
drospirenone and EE 368 22 1.48 (0.96, 2.29) 1.17 (0.76, 1.80)
levonorgestrel and EE 545 34 1.55 (1.09, 2.21) 1.20 (0.83, 1.74)
norethisterone and EE 75 11 4.00 (2.10, 7.62) 3.33 (1.69, 6.57)
Progestin only OC
norethisterone 146 11 1.90 (1.02, 3.52) 2.02 (1.09, 3.75)
Other
b 504 16 0.76 (0.46, 1.26) 0.69 (0.41, 1.15)
1 - >0 months before
Combination OC
desogestrel and EE 295 25 2.16 (1.42, 3.27) 2.09 (1.38, 3.16)
drospirenone and EE 1,472 61 1.01 (0.77, 1.31) 0.95 (0.73, 1.24)
levonorgestrel and EE 2,521 120 1.16 (0.96, 1.41) 1.11 (0.91, 1.36)
norethisterone and EE 372 19 1.25 (0.79, 2.00) 1.21 (0.76, 1.93)
Progestin only OC
desogestrel 690 17 0.59 (0.36, 0.96) 0.65 (0.40, 1.06)
norethisterone 483 13 0.64 (0.37, 1.12) 0.74 (0.43, 1.29)
Vaginal ring
etonogestrel and EE 356 13 0.88 (0.51, 1.54) 0.86 (0.49, 1.51)
Other
b 276 7 0.61 (0.29, 1.29) 0.60 (0.28, 1.28)
4 - >1 month before
Combination OC
desogestrel and EE 197 11 1.38 (0.75, 2.54) 1.27 (0.69, 2.35)
drospirenone and EE 1,227 56 1.11 (0.85, 1.47) 1.07 (0.80, 1.41)
levonorgestrel and EE 2,107 125 1.47 (1.21, 1.78) 1.40 (1.15, 1.70)
norethisterone and EE 302 21 1.74 (1.11, 2.72) 1.67 (1.06, 2.62)
Progestin only OC
desogestrel 817 34 1.01 (0.71, 1.43) 1.15 (0.81, 1.63)
norethisterone 417 16 0.93 (0.56, 1.54) 1.09 (0.66, 1.80)
Vaginal ring
etonogestrel and EE 352 12 0.82 (0.46, 1.47) 0.80 (0.45, 1.43)
Other
b 321 12 0.90 (0.51, 1.62) 0.89 (0.50, 1.60)
12 ->4 months before
Combination OC
desogestrel and EE 215 17 2.00 (1.21, 3.30) 1.86 (1.13, 3.09)
drospirenone and EE 1,475 79 1.32 (1.04, 1.67) 1.25 (0.99, 1.60)
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Exposure Exposed(n) Preterm (n) OR (95% CI) aOR
a
 (95% CI)
levonorgestrel and EE 2,605 122 1.14 (0.94, 1.39) 1.09 (0.89, 1.33)
norethisterone and EE 338 23 1.70 (1.11, 2.61) 1.61 (1.05, 2.49)
Progestin only OC
desogestrel 1,031 42 0.99 (0.72, 1.36) 1.13 (0.82, 1.55)
norethisterone 640 22 0.83 (0.54, 1.28) 0.95 (0.62, 1.47)
Vaginal ring
etonogestrel and EE 424 12 0.68 (0.38, 1.21) 0.67 (0.38, 1.20)
Transdermal patch
norelgestromin 295 10 0.82 (0.43, 1.54) 0.78 (0.41, 1.48)
Injectable
medroxyprogesterone 180 14 1.96 (1.13, 3.40) 1.83 (1.06, 3.18)
Other
b 267 8 0.72 (0.36, 1.46) 0.79 (0.39, 1.60)
a
adjusted for parity, maternal education, maternal pre-pregnancy BMI, maternal smoking, and maternal age at birth
b
hormonal contraceptive types with <10 exposed cases collapsed into a single “other” category
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